Drug Trial Radar · NCT04683250
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
244
Planned (sponsor's estimate)
Start
Dec 16, 2020
Primary completion
Mar 2030
Study completion Mar 2031
Sponsor
- Lead sponsor
- Taiho Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.
Conditions
- RET-altered Non Small Cell Lung Cancer
- RET-altered Solid Tumors
Interventions
TAS0953/HM06Drug
Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days
TAS0953/HM06Drug
Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 (dose-escalation): Maximum Tolerated Dose (MTD)Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Phase 1 (dose-expansion): Recommended Phase 2 dose (RP2D)Time frame: At the end of Cycle 1 (each cycle is 21 days), and at the end of every subsequent cycle (each cycle is 21 days) for approximately 10 months (or earlier if patient discontinues the study)
- Phase 2: Objective Response Rate (ORR) by independent central reviewTime frame: Approximately every 6 weeks for 6 months, then every 9 weeks during treatment, 7 days after the last dose, and every 3 months after the last dose (up to an average of 2 years) in patients without progressive disease.
Locations
29 sites in 4 countries. Site status is shown where the registry gives one.
Chao Family Comprehensive Cancer Center
Orange, California · Terminated
Stanford Cancer Center
Stanford, California · Terminated
Massachusetts General Hospital
Boston, Massachusetts · Terminated
Henry Ford Hospital
Detroit, Michigan · Terminated
START Midwest - Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan · Terminated
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Terminated
Memorial Sloan Kettering Cancer Center
New York, New York · Terminated
The Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee · Terminated
The University of Texas M. D. Anderson Cancer Center
Houston, Texas · Terminated
Cabrini Hospital
Malvern, Australia · Recruiting
Linear Clinical Research
Nedlands, Australia · Recruiting
GenesisCare North Shore
Saint Leonards, Australia · Recruiting
Aichi Cancer Center
Aichi, Japan · Recruiting
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan · Recruiting
Kanagawa Cancer Center
Kanagawa, Japan · Recruiting
Kurashiki Central Hospital
Okayama, Japan · Recruiting
Kindai University Hospital
Osaka, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan · Recruiting
Tohoku University Hospital
Sendai, Miyagi, Japan · Recruiting
Okayama University Hospital
Okayama, Okayama-ken, Japan · Recruiting
Kansai Medical University Hospital
Hirakata-shi, Osaka, Japan · Recruiting
Osaka International Cancer Institute
Osaka, Osaka, Japan · Recruiting
Shizuoka Cancer Center
Shizuoka, Shizuoka, Japan · Recruiting
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan · Recruiting
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan · Recruiting
Seoul National University Bundang Hospital
Seongnam, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.